Search results
Results from the WOW.Com Content Network
This is an alphabetically sorted list of all mental disorders in the DSM-IV and DSM-IV-TR, along with their ICD-9-CM codes, where applicable. The DSM-IV-TR is a text revision of the DSM-IV. [1] While no new disorders were added in this version, 11 subtypes were added and 8 were removed. This list features both the added and removed subtypes.
This is a list of mental disorders as defined in the DSM-IV, the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders.Published by the American Psychiatry Association (APA), it was released in May 1994, [1] superseding the DSM-III-R (1987).
Methamphetamine is known to possess a high addiction liability (i.e., a high likelihood that long-term or high dose use will lead to compulsive drug use) and high dependence liability (i.e., a high likelihood that withdrawal symptoms will occur when methamphetamine use ceases). Discontinuing methamphetamine after heavy use may lead to a post ...
The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse of the drug or other substances may lead to severe psychological or physical dependence. The complete list of Schedule II substances is as follows.
Methamphetamine is FDA approved for the treatment of ADHD and exogenous obesity. It is dispensed in the USA under the trademark name "Desoxyn" [22] and manufactured by Ovation Pharmaceuticals. [23] The levorotary form of methamphetamine, called levomethamphetamine, is an over-the-counter drug used in nasal decongestants inhalers. [24]
Substance intoxication is a transient condition of altered consciousness and behavior associated with recent use of a substance. [1] It is often maladaptive and impairing , but reversible. [ 2 ] If the symptoms are severe, the term "substance intoxication delirium " may be used. [ 3 ]
3,4-Dihydroxymethamphetamine (HHMA, 3,4-DHMA), or 3,4-dihydroxy-N-methylamphetamine, also known as α-methylepinine or α,N-dimethyldopamine, is the major metabolite of 3,4-methylenedioxy-N-methylamphetamine (MDMA).
Stimulant use disorder is a type of substance use disorder where the use of stimulants caused clinically significant impairment or distress. It is defined in the DSM-5 as "the continued use of amphetamine -type substances, cocaine , or other stimulants leading to clinically significant impairment or distress, from mild to severe". [ 1 ]